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Summary 
Recombinant human erythropoietin (rHuEPO) is an effective treatment for 
anaemia but concerns that it  causes  disease  progression  in cancer patients 
by activation of EPO receptors (EPOR) in tumour tissue have been contro- 
versial and have restricted its clinical use. Initial clinical studies were flawed 
because they used polyclonal antibodies, later shown to lack specificity for 
EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing 
have been reported in cancer cell lines at the mRNA level but investigations 
of these variants and their potential impact on tumour progression, have   
been hampered by lack of suitable antibodies.  The  EpoCan  consortium  
seeks to promote improved pathological testing of EPOR, leading to safer 
clinical use of rHuEPO, by producing well characterized EPOR antibodies. 
Using novel genetic and traditional peptide immunization protocols,  we  
have produced mouse and rat monoclonal antibodies, and show that sev-    
eral of these specifically recognize EPOR by Western blot, immunoprecipi- 
tation, immunofluorescence, flow cytometry and immunohistochemistry in 
cell lines and clinical material. Widespread availability of these antibodies 
should enable the research community  to  gain  a  better  understanding  of 
the role of EPOR in cancer, and eventually to distinguish patients who can   
be treated safely by rHuEPO from those at increased risk from treatment. 
Keywords: cancer anaemia, recombinant erythropoietin, erythropoietin 
receptor, antibody, risk assessment. 
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Anaemia is an independent prognostic factor for poor  sur- 
vival in cancer patients (Caro et al, 2001), but the use of 
recombinant human erythropoietin (rHuEPO) to treat these 
patients is controversial due to concerns about patient safety 
arising from Phase III clinical trials showing more rapid can- 
cer progression and reduced survival in subjects randomized   
to rHuEPO (Henke et al, 2003; Leyland-Jones et al, 2005; 
Miller et al, 2009). Consequently there has been a marked 
decline in the use of rHuEPO since 2007 (Hill et al, 2012). 
Clearly, the benefits of EPO treatment must be carefully bal- 
anced against the risk of enhanced cancer progression  for  
each patient. 
Erythropoietin functions by binding to its receptor (EPOR) 
on the surface membrane of erythroid progenitors and activat- 
ing JAK2/STAT5 signalling pathways (Jelkmann, 2010; Wenger 
& Kurtz, 2011). There is now evidence that growth factor 
receptor-mediated cell signalling pathways can overlap in can- 
cer cells. In a landmark study, Liang et al (2010) found that 
EPOR is co-expressed with human epidermal growth factor 
receptor-2 (HER2, also known as ERBB2) in breast cancer cell 
lines and tumour specimens. rHuEPO administered to patients 
antagonized trastuzumab treatment and resulted in shorter 
progression-free and overall survival in patients with HER2- 
positive metastatic breast cancer (Liang et al, 2010). 
Erythropoietin has pleiotropic actions and EPOR is 
expressed outside the  haematopoietic  compartment  (Lappin 
et al, 2002; Ghezzi et al, 2010; Vogel & Gassmann, 2011). 
EPOR is functionally active in endothelial cells (Anagnostou  
et al, 1994) and endothelial progenitor cells promoting vas- 
cular repair and endothelial regeneration (Trincavelli et al, 
2013). Moreover, EPO stimulates angiogenesis both in vitro 
and in vivo (Trincavelli et al, 2013). Positive effects of EPO 
treatment on the immune system have been documented 
(Mittelman et al, 2004; Prutchi-Sagiv et al, 2006, 2008; Katz  
et al, 2007; Lifshitz et al, 2010; Mausberg et al, 2011; Nairz   
et al, 2012; Oster et al, 2013). EPO has thrombotic effects, at 
least in vitro, as it increases plasminogen activator inhibitor-1 
release in HUVEC culture (Stasko et al, 2002). Patients with 
end-stage renal disease on high doses of rHuEPO have high 
haemoglobin levels, are associated with increased risk of car- 
diovascular and thrombotic events, and have reduced sur-  
vival (Smith et al, 2003; Provatopoulou & Ziroyiannis, 2011). 
These observations support the hypothesis that supraphysio- 
logical levels of circulating EPO could lead to enhanced 
tumour growth, neovascularization and thrombosis in some 
cancer patients. Recommendations for the use of erythropoi- 
esis-stimulating agents (ESAs) in patients with cancer have 
been published (Rizzo et al, 2010). 
To understand the increased  risk  of  administering  
rHuEPO to patients with cancer, it is imperative  to examine  
its effects in tumour tissue. Angiogenic factors, such as vas- 
cular endothelial growth factor A (VEGFA), platelet-derived 
growth factors (PDGFs), fibroblast growth  factors  (FGFs)  
and angiopoietins are often elevated in the tumour environ- 
ment. PDGFBB targets perivascular cells to nascent    vascular 
networks (Abramsson et al, 2003) and modulates tumour 
angiogenesis by increasing EPO production in stromal cells, 
leading to the induction of endothelial cell proliferation, 
migration, sprouting and tube formation (Xue et  al,   2012). 
Contentious inferences were drawn from clinical  studies 
that were based on immunohistochemistry (IHC) using anti- 
bodies, but later shown to lack specificity  for EPOR (Elliott   
et al, 2006; Brown et al, 2007). Thus, investigation of EPOR 
expression and function relies heavily on the availability of 
specific anti-EPOR antibodies. 
The EU-based EpoCan project addresses safety concerns 
related to EPO treatment and is investigating the  risks  of  
EPO treatment using mouse models, human clinical samples 
and patient databases. The studies focus on the long-term 
effects of EPO treatment on tumour growth  and  incidence,  
the role of EPO in angiogenesis and its association with 
thromboembolic events in cancer and cardiovascular disease. 
An important initial objective was to prepare a  range  of  
highly specific monoclonal antibodies against human EPOR. 
To this end, a cohort of 15 EPOR mouse and rat monoclonal 
antibodies were produced and evaluated for different applica- 
tions. Here we report on the characterization of four of these 
antibodies, which have proved suitable for a range of appli- 
cations. 
 
Materials and methods 
 
Cell lines 
The human cell lines used were: megakaryoblastic leukaemia 
cells, UT-7; acute lymphocytic leukaemia cells, REH; pre-B 
cells, NALM6; breast cancer cells, MDA-MB-231; human 
embryonic kidney cells HEK293T, and its derivative,  
BOSC23; and lung cancer cells, A549. 
 
Tissue sections 
Formalin-Fixed Paraffin wax-Embedded (FFPE) tissue sec- 
tions and bone marrow aspirates were obtained under agree- 
ment with the Northern Ireland Biobank (Ethical approval 
reference  NIB12-0044). 
 
Monoclonal antibody generation by genetic 
immunization 
Monoclonal antibodies were generated using cDNA con- 
structs encoding the extracellular domain (ECD) of hEPOR 
cloned into proprietary immunization and screening vectors. 
Anti-tag antibodies were used to confirm expression after 
transient transfection of the cDNA constructs into mamma- 
lian cells, in vitro. The immunization constructs were  
adsorbed onto the surface of gold particles and introduced 
intradermally into mice and rats using a BioRad gene gun 
(Bio-Rad GmbH Mu¨nchen, Germany), with several cDNA 
boosts,   following   proprietary   protocols.   This   cDNA was 
 
taken up and translated by skin  cells,  whereby  the  protein 
was brought to the cell surface and finally secreted to allow   
an optimal immune response against the EPOR  ECD.  The 
sera were tested against both the ECD and full-length EPOR 
construct, the cDNA of which had been transiently transfect- 
ed into mammalian  cells. 
 
Monoclonal antibody generation using synthetic  peptides 
The amino acid sequence of hEPOR was analysed using 
hydrophilicity/hydrophobicity software to identify peptide 
regions representing potential epitopes. In total, six peptides 
(h1–h6) were chosen for peptide synthesis of which five were 
located in the cytoplasmic domain (h2–h6) as shown for 
hEPOR (Table I). The peptides were conjugated with keyhole 
limpet haemocyanin for immunization and  with  ovalbumin 
for screening in peptide  enzyme-linked  immunosorbent  
assays (ELISA). Immunization was carried out intraperitone- 
ally with one group of six peptides (h1–h6) into two cohorts  
of three rats. The peptides were mixed with  complete  
Freund’s adjuvant for the initial immunization, followed by 
several boosts with incomplete Freund’s adjuvant. Following 
immunization of three animals per cohort,  sera were  tested  
for positivity in a peptide ELISA against ovalbumin-peptide 
conjugate mixes, corresponding to their immunogen mix- 
tures. After lymphocyte fusion, the resulting hybridoma 
supernatants were screened against each individual ovalbu- 
min-peptide conjugate in the same ELISA assay to identify 
antibodies against specific peptides. 
 
Flow cytometry 
Flow cytometry was performed essentially as described (Lif- 
shitz et al, 2010). Cell suspensions were analysed on a FAC- 
Sort flow cytometer (Becton Dickinson, Oxford, UK) and the 
results were analysed using WinMDI software (J.Trotter free 
download, http://winmdi.software.informer.com/2.8/). Anti- 
HA antibody (MMS-101R) was from Covance  (Princeton,  
NJ, USA). Fluorescein isothiocyanate (FITC)-conjugated 
AffinityPure Goat Anti-Mouse IgG and FITC-conjugated 
Affinity Pure Goat Anti-Rat IgG were from Jackson Immu- 
noResearch Laboratories Inc. (West Grove, PA, USA). 
 
 
 
Table  I.  Choice of human EPOR peptides for  immunization. 
Human EPO-R peptides Location Exon 
h1: PPPNLPDPKFES Extracellular domain 1 
Immunofluorescence 
Cells seeded on glass cover slips (A549, MDA-MB-231, COS7 
and HEK293T) or collected in a 1·5 ml tube  (UT-7)  were 
fixed in 3% paraformaldehyde in phosphate-buffered saline 
(PBS) at room temperature (RT) for 30 min. After incuba-   
tion in quenching buffer (0·1% Triton, 5%  fetal  bovine 
serum, and 2% bovine serum albumin) at RT for 1 h, cells 
were incubated with primary antibodies diluted in quenching 
buffer at RT for 1 h. After washing with PBS, cells were 
incubated with secondary antibodies for 1 h at RT. Nuclei were 
stained with 2·5 lmol/l DRAQ5(ab108410; Abcam, 
Cambridge, MA, USA) for 30 min at RT. Confocal fluores- 
cent images were obtained by a TCS SP5 II confocal micro- 
scope (Leica, Wetzlar, Germany) with a 63x/1.4NA objective 
or a CSU10 spinning disc unit coupled to a Zeiss Axiovert 
200M microscope with a 100x/1.3NA oil immersion objec- 
tive. For some experiments, fusion proteins of enhanced cyan 
fluorescent protein (ECFP) and EPOR were made by cloning 
cDNA encoding for the hEPOR into the pECFP-N1 vector 
(Clontech, Mountain View, CA, USA) between HindIII and 
BamHI. A construct specific for the intracytoplasmic domain 
(ICD) of EPOR was generated by replacing the extracellular 
and transmembrane domain in the  described  construct  by  
that of the epithelial growth factor receptor (EGFR) (Gross     
et al, 2014). For transient transfections plasmid DNA was 
mixed with the transfection reagent Turbofect (Thermo Sci- 
entific, Waltham, MA, USA) according to the supplier’s rec- 
ommendations. The cells were incubated for 24 h with the 
transfection mix and subjected to immunofluorescence stain- 
ing as described. 
 
Generation of EPOR-silenced cells 
Human EPOR (sc-37092-V) and control (sc-108080) shRNA 
lentiviral particles (Santa Cruz Biotechnology, Dallas, TX, 
USA) were used to generate stable transfectants in MDA- 
MB-231 breast cancer cells and A549 lung carcinoma cells. 
After lentiviral infection, infected cells were selected with 
puromycin (1 lg/ml) to finally generate MDA-MB-231-shE- 
POR, A549-shEPOR cells and their corresponding MDA- 
MB-231-shSCR and A549-shSCR control cells. Following 
puromycin selection for 11–18 d, cells were lysed in Laemmli 
buffer and subjected to Western blot analysis using the 
GM1201 antibody (see Table II). 
 
Western blot analysis 
Cells were lysed in Laemmli buffer. Western blots were per- 
h2: KIWPGIPSPESEFEG 
LFTTHKGN 
Intracytoplasmic domain 7 formed using 10% sodium dodecyl sulphate (SDS)-polyacryl- 
amide   gels.   Membranes   were   incubated   with   a   1:1000 
h3: VEPGTDDEGPL Intracytoplasmic domain        8 
h4: LPRNPPSEDLPGPG Intracytoplasmic domain       8 
h5: PSSQLLRPWTLC Intracytoplasmic domain       8 
h6: GDSQGAQGGLSDGPYSN      Intracytoplasmic domain       8 
dilution in Tris-buffered saline (TBS)-Tween 20 (TBS-T) 
buffer of the indicated anti-EPOR antibody at 4°C overnight. 
Membranes were incubated with the corresponding second-  
ary antibody  at RT for  1 h and, finally, washed  three     times 
 
Table II.  Characteristics of the four selected EPOR monoclonal   antibodies. 
 
Immunogen Subclone name Isotype Epitope location Applications 
Peptide h6 GM1201 rIgG2b Intracytoplasmic domain WB, IP, IF, IHC 
Genetic immunization GM1202 mIgG1 Extracellular domain IP, IF, FACS 
Genetic immunization GM1203 mIgG1 Extracellular domain IP, IF, FACS 
Genetic immunization GM1204 rIgG2a Extracellular domain FACS 
WB, Western blotting; IP, immunoprecipitation; IF, immunoflourescence, IHC, immunohistochemistry; FACS, fluorescence-activated cell   sorting. 
 
with TBS-T buffer for 10 min. Immunolabeling was detected 
by enhanced chemiluminescence (SuperSignal West Femto 
Maximum Sensitivity Substrate; Thermo Scientific) and visu- 
alized with a digital luminescent image analyser  (Image  
Quant LAS400 mini; GE Healthcare Life Sciences, Bucking- 
hamshire, UK). 
 
Coupling of antibodies for immunoprecipitation 
For immunoprecipitation (IP), anti-EPOR antibodies or anti-
HA antibodies (clone 12CA5, Abcam) were covalently 
coupled to protein-A agarose (Immunosorb A, Medicago, 
Uppsala, Sweden). Antibody (2 lg) was incubated with 5 ll 
Protein-A bead slurry in PBS for 1 h at RT. Beads were 
washed with sodium borate (0·2 mol/l, pH 9·0) and the anti- 
body  was  cross-linked   to   protein-A   upon   addition   of   
40  mmol/l dimethylpimelimidate. 
 
Cell transfection, protein extraction and IP 
Plasmid encoding the N-terminal HA-tagged hEPOR was 
transiently transfected into HEK-293T cells with calcium- 
phosphate (Graham & van der Eb, 1973) and harvested 48 h 
later. Cell extracts were prepared in IP buffer with 1% Triton 
X-100.  Protein  extracts  were  cleared  by   centrifugation   
(10 000 g; 20 min), protein concentration determined by 
BioRad-DC assay and IP performed using 40 lg extract from 
transfected HEK-293T cells, 750 lg of UT-7 cells or 1·5 mg 
extract from A549 and MDA-MB231 cells. Proteins were 
diluted with IP buffer and IP was performed in the presence   
of 0·5% Triton X-100 for 2 h at 4°C. After 3 washes with  
0·5% Triton X-100 IP buffer, EPOR protein was eluted by 
boiling in Laemmli sample buffer (pH 6·8) for 5 min, loaded 
on a SDS-polyacrylamide gel and analysed by Western blot 
using GM1201 antibody. 
 
Mass spectrometry – Nano-high performance liquid 
chromatography – MS/MS 
Four milligram of UT-7 cell extract was immunoprecipitated 
with GM1202 and GM1203 (see Table II) agarose-coupled 
antibodies (mixture of 1:1, 6 lg antibodies each). After 
extensive washing, the precipitated  proteins  were  separated 
by a 10% SDS-polyacrylamide gel electophoresis and visual- 
ized  with  Coomassie  Blue.  Protein  digests  of  the  gel piece 
covering the 65 kD region were analysed using an UltiMate 
3000 nano-HPLC system (Dionex, Germering, Germany) 
coupled to an LTQ Orbitrap XL mass spectrometer. An in-
house fritless fused-silica microcapillary column (75 lm i.d., 
280 lm o.d.) packed with 10 cm of 3-lm reversed-phase C18 
material (Reprosil, Dr Maish GmbH, Ammerbuch- Entringen, 
Germany) was used. The gradient  (solvent  A,  0·1% formic 
acid; solvent B, 0·1% formic acid in 85% acetonitrile) started 
at 4% B. The concentration of solvent B was increased 
linearly from 4 to 50% over 50 min and from 
50 to 100% over 5 min. A flow rate of 250 nl/min was  
applied. Data analysis was performed using Proteome 
Discoverer 1.3 (ThermoScientific) with search engine Sequest 
(http://fields.scripps.edu/sequest/). Precursor mass tolerance 
was set to 10 ppm, fragment mass tolerance was 0·8 Da. Raw 
data obtained by liquid chromatography-electrospray ioniza- 
tion mass spectrometry (LC-ESI-MS) were searched against 
the Homo sapiens protein database extracted  from  the 
NCBInr database using false discovery rate (FDR) for peptide 
evaluation.  Only  peptides  with   a   significance   threshold 
of 0·01 (99% confidence) or less were used for protein 
identification. 
 
Immunohistochemistry 
To test the suitability of antibodies for clinical applications in 
FFPE material, we used UT-7, REH and NALM-6 cell lines, as 
they have differential endogenous EPOR expression. They were 
grown to confluence in 29 T75 flasks, removed and fixed in 
10% formal saline (BCS Biosciences Ltd, Cambridge, UK) 
overnight and processed to paraffin wax. Sections were pre- 
pared and stained by all antibodies at concentrations of 2– 10 
lg/ml following pressure cooking antigen retrieval, and using 
anti-rabbit/-mouse Envision (Dako, Cambridge, UK), or 
peroxidase-conjugated anti-rat immunoglobulin (Sigma- 
Aldrich, Gillingham, UK) localization. Sections were prepared 
from bone marrow samples and stained at 4 lg/ml concentra- 
tion using automated IHC (Discovery XT; Roche Tissue Diag- 
nostics, Burgess Hill, UK) and CC1 conditioning. 
Bone marrow aspirate smears and cultured erythroid pro- 
genitor cells were mounted on glass slides and fixed over- 
night in 95% methylated ethanol. After washing in water,  
slides were flooded with PBS pH 7·0 and primary antibodies 
incubated overnight at 4°C (rat anti-EPOR GM1201 Aldev- 
ron, Freiburg, Germany) and rabbit anti-ferritin  H    (ab75972, 
 
 
 
 
Fig 1. Specificity of individual anti-EPOR hybridoma clones. (A) Hybridoma supernatants were analysed by flow cytometry on cells transiently 
transfected with the human EPOR extracellular domain (ECD) cDNA cloned into a proprietary Aldevron test vector (green curves). Depending 
on the antibody source, a goat anti-mouse or anti-rat IgG R-phycoerythrin (R-PE) conjugate were used as secondary antibodies. Negative con- 
trols: Mammalian cells, transfected with an irrelevant control cDNA cloned in the corresponding expression vector (red curves). (B) BOSC23 cells 
expressing HA-tagged hEPOR or EGFR were incubated at 4°C with primary antibodies (10 lg/ml) followed by fluorescein isothiocyanate (FITC)- 
conjugated secondary antibodies. Black line: GM1202, GM1203 and GM1204; Green line: anti-HA antibody. Red and blue lines: secondary anti- 
body only. Depending on the antibody source, a goat anti-mouse IgG R- conjugate (#1030-09, Southern Biotech, Birmingham, AL, USA), or a 
goat anti-rat IgG R-PE conjugate (#3030, Southern Biotech) were used as secondary antibodies at 10 lg/ml. As negative control BOSC23 cells, 
transfected with an irrelevant control cDNA cloned into the corresponding expression vector, were incubated with each monoclonal antibody and 
detected with the secondary antibody described above (black curves). (C) Cells were incubated with primary antibodies (4 lg/ml for UT-7 cells; 10 
lg/ml for A549 and MDA-MB-231 cells), followed by FITC-conjugated secondary antibodies (15 lg/ml). Black line: GM1202, GM1203 and 
GM1204; Red line: secondary antibody only. EPOR, erythropoietin receptor; EGFR, epithelial growth factor receptor. 
Abcam, Cambridge, UK) or rabbit anti-glycophorin C 
(ab108619, Abcam) at 4 lg/ml. FITC anti-rat (Millipore, 
Billerica, MA, USA) and Alexa Fluor 568 anti-rabbit (Life 
Technologies, Paisley, UK) were used to localize immunore- 
activity for 2 h at 37°C. Cell preparations were mounted in 
aqueous mounting medium containing 40 ,6-diamidino- 2-
phenylindole (DAPI, Aquilant Scientific, Belfast, UK). 
 
Results 
 
Monoclonal antibodies generated by genetic 
immunization against hEPOR-ECD 
Four murine and five rat mother hybridomas were preselect-ed 
for their ability to recognize the hEPOR ECD constructs in flow 
cytometry. Purified monoclonal antibodies were tested by flow 
cytometry at 1 lg/ml (Fig 1A–C). 
Monoclonal antibody generation using synthetic  peptides 
Supernatants from the stable mother clones were pre-tested   
for the selection of the best mother clones for each assay 
(Western blots, IP, IHC, immunofluorescence and flow 
cytometry) with respect to signal strength and  specificity.  
The chosen mother clones were then subcloned by serial 
dilution, expanded, isotyped and antibodies purified using 
protein G columns and resuspended in PBS to a given con- 
centration (1–2 mg/ml). The results of the chosen subclones 
that revealed the most unequivocal results in the  various  
assays were generated against human peptide 6, which is 
located close to the C-terminal region of EPOR (Table I). 
 
Systematic nomenclature of  monoclonal antibodies 
Of 15 monoclonal antibody mother clones,  four  were  
selected for subcloning and additional testing (Table   II). 
(A) 
(B) 
(a) 
(C) 
(a) 
(b) (b) 
(c) 
(c) 
 Flow cytometry analysis of EPOR 
The GM1202, GM1203 and GM1204 antibodies, raised 
against the ECD, recognized hEPOR by fluorescence-acti- 
vated cell sorting (FACS) analysis, on Bosc23 cells transfected 
with HA tagged hEPOR or EGFR cDNA constructs. The 
three antibodies showed similar levels of hEPOR expression 
as compared to anti-HA antibody (positive control). Isotype 
controls (data not shown) and secondary antibodies were 
used as negative controls. The specificity of the antibodies 
was verified by the lack of reactivity in HA-EGFR transfected 
cells. Using FACS analysis, the same antibodies also detected 
endogenous hEPOR in UT-7, A549 and MDA-MB-231 cells. 
hEPOR was detected with higher sensitivity in UT-7 cells 
(4 lg/ml antibody concentration) than in A549 and MDA- 
MB-231 (10 lg/ml). 
 
Immunofluorescence 
COS7 cells were transfected with HA-hEPOR cDNA and 
stained with GM1202 and GM1203 directed against the ECD 
and GM1201 directed against the ICD (Fig 2A) using anti-HA 
as a positive control. The three antibodies detected hEPOR and 
specificity was verified using isotype controls (data not shown). 
HEK293T cells were transfected with DNA encoding a fusion 
protein of ECFP and EPOR, incubated for  24 h and then 
stained with GM1201, directed against the ICD, and GM1202 
or GM1203, directed against the ECD,  of  EPOR (Fig 2B). 
Colour coding was set to  equal  values for ECFP and 
Alexa555 (secondary antibody label) channels with the 
exception listed in the legend to Fig 2B. For the anti-EPOR 
antibodies GM1202 and GM1203 (rows 2 and 3), perfect co-
localization at the membrane of immunofluorescence with 
ECFP fluorescence was observed, indicating specific recogni- 
tion of EPOR protein by the antibodies. In contrast, the anti- 
bodies did not detect the ECFP-EGFR-EPOR fusion protein, 
which was sufficiently expressed (as can be seen in the ECFP 
channel) and therefore served as a negative control (upper 
row). GM1201 antibody was only able to detect  EPOR 
protein in permeabilized cells,  indicating correct orientation 
of the ECFP-EPOR fusion protein and supporting its speci- 
ficity for the ICD of EPOR. Interestingly, this antibody also 
detects the ICD in a fusion protein made  from ECFP, the 
ECD of EGFR and the ICD of EPOR. Reactivity of the 
GM1201, GM1202 and GM1203 antibodies with hEPOR was 
also  demonstrated  in  UT-7,  A549  and  MDA-MB-231 cells, 
showing significantly higher sensitivity in UT-7 cells. 
 
 
Endogenous EPOR expression in tumour cell lines 
The ability of the antibodies to recognize endogenous EPOR 
expression in tumour cells was tested by immunofluorescence 
(Fig 3) and Western blot analysis (Fig 4) using the UT-7 cell 
line as well as EPOR-silenced breast carcinoma MDA-MB-231 
cells and EPOR-silenced lung carcinoma A549 cells (shE- 
POR) and the corresponding control cells (shSCR). RNA 
analysis in these cells showed that the EPOR mRNA level in 
UT-7 is 270 ± 8 times higher than in MDA-MB-231 control 
cells (MDA-MB-231-shSCR) and  56 ± 2  times  higher  than 
in A549 control cells (A549-shSCR). Further RNA analysis in 
EPOR-silenced MDA-MB-231 and A549 cells showed that 
EPOR mRNA expression declined by 82 ± 3% and 70 ± 3% 
respectively, which validated these cellular models for testing 
GM1201 antibody by Western blot. In line with these RNA 
data, Western blotting showed a main signal around 63 kDa    
in these three cell lines and was negative for EPOR-silenced 
cells (Fig 4). This signal was much higher in UT-7 than in 
MDA-MB-231 and A549 control cells, reflecting that Western 
blot signal parallels EPOR mRNA levels in these cells. More- 
over, GM1201 has the potential to detect higher molecular 
weight EPOR forms, which are much weaker than the main   
63 kDa form. Collectively, these data indicate that GM1201 
reliably detects endogenous EPOR by Western  blotting. 
 
Identification of antibodies that specifically 
immunoprecipitate overexpressed and endogenous human 
EPOR 
Using overexpressed HA-hEPOR as a source, GM1201, 
GM1202 and GM1203, were identified as antibodies with the 
highest immunoprecipitating efficiency (Fig 5A). Of note, the 
rat-derived antibody GM1201 was as efficient as the com- 
mercial anti-HA-tag antibody by IP (Fig 5A). The GM1201 
antibody was also used to detect untagged immunoprecipi- 
tated hEPOR in Western blots. Besides this antibody, two 
mouse-derived antibodies directed against the ECD of EPOR, 
GM1202 and GM1203, were able to efficiently recover 
endogenous hEPOR in immunoprecipitates from UT-7, A569 
and MDA-MB-231 cells (Fig 5B–D). In the case of very low 
endogenous hEPOR expression in A549 or MDA-MB-231 
cells, the use of these mouse antibodies prevented the detec- 
tion of cross-reacting bands, which were precipitated if the 
same antibody (GM1201) was used in IP and Western blot 
[A549: Fig 5C (*); MDA-MB-231: data not  shown]. 
In all cases and with all antibodies, IP was able to signifi- 
cantly enrich the EPOR compared to the cell lysate (10% of  
the IP input). Specificity of the  immunoprecipitated  bands 
was confirmed by knockdown of EPOR using shRNAs in 
A549 cells and MDA-MB-231 cells (Fig 5C, D). The recovery 
of hEPOR in immunoprecipitates using GM1202  and  
GM1203 antibodies was further confirmed by Nano-HPLC– 
MS/MS, where seven EPOR-specific peptides were identified 
in trypsin-digested samples (Fig 6). Together, these data 
revealed a specific and highly efficient hEPOR immunopre- 
cipitating capacity of GM1201, GM1202 and GM1203. 
 
Immunohistochemistry 
Differential expression of EPOR mRNA expression was con- 
firmed  in  NALM-6,  REH  and  UT-7  cell  lines  by   Q-PCR 
 
 
GM1201 GM1202 GM1203 ANTI-HA 
 
 
Fig 2. Immunofluorescence of transiently transfected hEPOR. (A) Cos7 cells were seeded on glass coverslips and transfected with HA-tagged hEPOR 
cDNA. Primary antibodies (and isotype matched controls – data not shown) were used at a 7 lg/ml, and secondary antibodies – at 4 lg/ml. Nuclei 
were stained with DAPI. Confocal fluorescent images were obtained with a LEICA TCS SP5 II confocal microscope with 63x/1.4NA objective. (B) 
HEK293T cells were transfected with plasmids encoding the indicated fusion proteins and hEPOR for 24 h, and stained with GM1201 (intracytoplas- 
mic domain; ICD) and GM1202 or GM1203 (extracellular domain; ECD). Colour coding is set to equal values for ECFP and Alexa555 channels 
except for the following recording: antibody GM1201 in ECFP-EGFR-EPOR transfected cells (antibody channel 8x less sensitive). All antibodies show 
perfect co-localization with the EPOR-ECFP (enhanced cyan fluorescent protein) chimaeras. Staining disappears when the ECD and the transmem- 
brane domain of EPOR are substituted by that of EGFR except for the GM1201 antibody that has its epitope in the ICD. Localization differences are 
mostly due to different epitopes of the respective antibodies (GM1201: ICD vs.GM1202 and GM1203: ECD). Confocal fluorescent images were 
obtained by a Zeiss Axiovert 200M microscope equipped with a CSU10 spinning disc (Yokogawa, Tokyo, Japan) and a 100x/1.3NA oil immersion 
objective. EPOR, erythropoietin receptor; EGFR, epithelial growth factor receptor; ECFP, enhanced cyan fluorescent protein. 
 
(Fig 7A). The rat antibody GM1201 showed strong staining    
in UT-7 cells and differential immunoreactivity  between  
FFPE REH (relatively high endogenous EPOR) and FFPE 
NALM-6  (relatively  low  EPOR),  see   Fig 7B,   C.   On   
high magnification, this was seen to be cytoplasmic in 
distribution. 
GM1201 was tested on FFPE non-erythroid cells, non-small 
cell lung carcinoma A549 and breast cancer MDA-MB-231 cell 
lines as knockdown models where lentiviral particles generated 
from three independent shEPOR sequences were used to infect 
MDA-MB-231 and A549 cells. A decline in EPOR protein was 
observed. Specificity of the antibodies towards EPOR in these 
two latter cell lines was ensured by the lack of immunoreactivity 
with the corresponding 
EPOR-silenced cells. High magnification confirmed reduced 
cytoplasmic immunoreactivity of shEpoR cells  compared  
with those derived from cells treated with scrambled  
sequences (Fig 7D, E). Summary results for GM1201 immu- 
noreactivity, compared with GM1202, GM1203 and GM1204 
are presented in Table  III. 
Immunoreactivity was found in erythroid cells in erythro- 
blastic islands using the rat antibody GM1201, while meta- 
myelocyte and neutrophil band forms were negative (Fig 7F). 
Immunoreactivity was also observed in cultured erythroid 
progenitor   cells   (Fig 7G)   and   bone   marrow   aspirate 
(Fig 7H). Furthermore, GM1201 immunoreactivity co-local- 
ized with the erythroid differentiation antigens ferritin H and 
glycophorin C (Fig 7G,  H). 
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(A) GM1201 
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Fig 3. Detection of endogenous hEPOR by immunofluorescence. UT-7 cells were collected and fixed in 3% paraformaldehyde in phosphate-buf- 
fered saline at room temperature (RT) for 30 min. Primary antibodies (and isotype controls – not shown) were diluted to 4 lg/ml in quenching 
buffer. Secondary antibodies [fluorescein isothiocyanate (FITC)-conjugated AffinityPure Goat Anti-Mouse IgG for GM1202 and GM1203 antibod- 
ies and FITC-conjugated AffinityPure Goat Anti-Rat IgG for the GM1201 antibody] were diluted to 4 lg/ml. MDA-MB-231 and A549 cells were 
seeded on glass coverslips. Primary antibodies (and Isotype controls – not shown) were diluted to 20 lg/ml and secondary antibodies were used at 
7·5 lg/ml. Nuclei were stained with DRAQ5 (2·5 lmol/l) for 30 min at RT. Confocal fluorescent images were obtained by a LEICA TCS SP5        II 
confocal microscope with a 63x objective. 
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overlap of cell signalling pathways that has pathogenic signif- 
icance (Ghezzi et al, 2010). 
Previous immunohistochemical studies on tumour tissue 
have drawn controversial conclusions  about  the  expression 
of EPOR, based on antibodies that were later shown to cross- 
react with other cellular proteins (Elliott et al, 2006; Brown    
et al, 2007). The ideal antibody for IHC would be monoclonal 
rather than polyclonal, possess immunoreactivity against a 
defined EPOR domain and lack cross-reactivity with other  tis- 
Fig 4. EPOR Western blot with GM1201 antibody.  MDA-MB-231 
and A549 cells were seeded in 60-mm plates at subconfluency and 
maintained for 72 h. UT-7 cells were  grown in  T-25 flasks  for  48– 
72 h. Then MDA-MB-231 and A549 plates as well as UT-7 pellets 
were lysed in 350 ll of Laemmli buffer 19. Cell lysates of UT-7 cells 
(0·2 ll) and EPOR-silenced MDA-MB-231 and A549 cells (shEPOR) 
(15 ll) as well as their corresponding controls (shSCR) (15 ll) were 
subjected to Western blot analysis with GM1201 antibody. Tubulin 
was used as loading control. The black arrowhead indicates the main 
specific EPOR Western blot signal (which specifically declines in 
EPOR-silenced cells), and the white arrowhead indicates the non- 
specific signal (does not decline in EPOR-silenced cells). 
 
 
Discussion 
A spectrum of strongly held views concerning EPOR func- 
tion in tumours is evident in the literature, ranging from  
claims that malignant cells are devoid of functional EPOR- 
mediated  signalling  pathways  to  assertions  that  there  is  an 
sue constituents. Unfortunately, most studies reported to date 
have used polyclonal antibodies or monoclonal antibodies of 
undefined specificity. Undoubtedly, the resulting discrepancies 
have masked the important debate about the safety of treating 
anaemic cancer patients with rHuEPO. Two other related fac- 
tors that have received scant consideration are the occurrence 
of EPOR splice variants (Arcasoy et al, 2003) and the possible 
involvement of a heterodimeric form of the receptor compris- 
ing one EPOR and one common b chain component (Brox- 
meyer, 2013). Whereas homodimeric EPOR has been 
extensively studied, the existence of the heterodimeric complex 
is debated and requires further study. 
The aim of the EpoCan consortium is to produce, charac- 
terize and validate a panel of EPOR monoclonal antibodies  
that would be readily available to the research community. 
These include antibodies raised against the ECD of EPOR for 
FACS  analysis;  those  that  recognize  the  denatured    EPOR 
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Fig 5. Antibodies that immunoprecipitate hEPOR. (A) Human HA-EPOR expressing plasmids (HA-hEPOR) or the empty control vector (Ctr. 
vector) were transfected in HEK293T cells. Precipitated EPOR was detected using the GM1201 antibody. 1/10 of the extract (4 lg) was loaded as  total 
cell extract (TCE). Mouse anti-HA antibody 12CA5, (HA), was used as a positive IP control, mouse IgG was used as a negative control (Ctr. 
IP). GM1201, GM1203: GM1201 antibodies or GM1203 antibodies coupled to Protein-A agarose were incubated in the absence of cell 
extract and loaded. (B) IP of EPOR from UT-7 cells. Ctr. IP: IP with normal mouse antibodies. Ctr. GM1203, Ctr. GM1201: Antibodies coupled 
to Protein-A agarose were incubated in the absence of cell extract. TCE: 10% of the input for the IP (75 lg) was loaded. (C) IP of hEPOR from   
A549 lung carcinoma cells expressing control (shSCR) and three EPOR-specific small hairpin RNA (shEPOR). GM1201 was used for Western blot 
detection. Cross-reacting bands (*) were detected when GM1201 was used in IP and WB. Ctr. IP: IP with normal mouse antibodies; Ctr 
GM1203, Ctr. GM1201: antibodies coupled to Protein-A agarose incubated in the absence of cell extract. TCE: 10% of the protein input for the 
IP (150 lg) was loaded. (D) IP of hEPOR from MDA-MB-231 cells transfected with shSCR or shEPOR. TCE: 10% of the protein input for the IP 
(150 lg) was loaded. TCE, total cell extract; IP, immunoprecipitation; Ctr.,    control. 
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Fig 7. Immunocytochemical analysis of anti-EPOR antibodies in FFPE cancer cell lines and normal tissues. (A) Relative mRNA expression of EPOR 
in NALM-6, REH and UT-7 cell lines depicted as fold-change relative to NALM-6; n = 3, error bars indicate the standard error. (B) EPOR immuno- 
cytochemistry using GM1201 (4 lg/ml) in FFPE UT-7 cells. (C) EPOR immunoreactivity using GM1201 (4 lg/ml) in FFPE REH human pre-B ALL 
cells compared with FFPE NALM-6 human non-T/non-B ALL cells. (D) EPOR immunocytochemical analysis using GM1201 (4 lg/ml) in FFPE 
MDA-MB-231 cells. shEPOR cells represent parental cells transfected with three EPOR-specific shRNA seuences. (E) EPOR immunocytochemical 
analysis using GM1201 (4 lg/ml) in FFPE A549 cells. shEPOR cells represent parental cells transfected with three EPOR-specific shRNA sequences. 
(F) Immunohistochemical staining of bone marrow for EPOR. Bone marrow aspirate from a patient with polycythaemia vera stained with rat anti- 
EPOR (GM1201). Red arrow denotes an erythroblastic island consisting of a central macrophage surrounded by erythroblasts (brown staining). 
Nuclei were counterstained with haematoxylin (blue). Green arrows denote metamyelocytes and neutrophil band forms, which are clearly negative 
for EPOR staining. Final magnification 9750. (G) Immunohistochemical dual staining of erythroid progenitor cells. To illustrate erythroblast differ- 
entiation, cryopreserved bone marrow mononuclear cells were cultured for 14 d in MethoCultTM H4034 Optimum and dual stained with rat anti- 
EPOR (GM1201) and either rabbit anti-ferritin H or rabbit anti-glycophorin C. Co-immunoreactivity of EPOR (a, green) and ferritin heavy chain (b, 
red) is evident during erythroid differentiation (c, merge). EPOR is expressed more prominently in an early erythroblast (green; d and f) and to a les- 
ser degree in later stages as demonstrated by cells with glycophorin C expression (red; e and f). Nuclei were counterstained with DAPI (blue). Cultures 
were obtained from the Stem Cell Technologies Human Bone Marrow Proficiency Testing Program and used with permission. Final magnification 
9630. (H) Immunohistochemical dual staining of bone marrow. Bone marrow aspirate from a patient with erythroid hyperplasia dual stained with    
rat anti-EPOR (GM1201) and either rabbit anti-ferritin H or rabbit anti-glycophorin C showing co-immunoreactivity of EPOR (a, green) and ferritin 
H (b, red) in panel c (merged). EPOR (d, green) and glycophorin C (e, red) show similar cellular localization (merged images, f). The red star in (d–f) 
indicates a differentiating erythroblast with low immunoreactivity for both EPOR and glycophorin C. Nuclei were counterstained with DAPI (blue). Final 
magnification 9630. All slides were scanned using the Hamamatsu Nanozoomer 2.0 HT scanner, C9600 series. Each specimen was scanned at brightfield 
409 magnification using nine layers and 3·0 lm spacing, with an off set of either 0 or +3. Scale bars, 10 lm. 
 
 
Fig 6. Identification of hEPOR by Nano-LC-ESI-MS/MS of GM1202 and GM1203 immunoprecipitates. (A) Illustration of identified hEPOR spe- 
cific peptides in the amino acid sequence of EPOR Precursor P19235. Identified specific peptides are schematically illustrated as green boxes and 
highlighted in red in the amino acid sequence. (B) The table represents the amino acid sequences of the identified peptides (1–7), their singly 
protonated molecular ions [M+H+], charge states and cross-correlation Xcorr values. (C) Tandem mass spectroscopy ion trap collision-induced 
dissociation (CID) spectra of peptides (1–7). Fragments used for search: b; b-H2O; b-NH3; y; y-H2O; y-NH3. 
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Table III.  Specificity of EPOR antibodies in FFPE cell line models. 
 
 
 
 
REH/NALM-6 model 
 
shEPOR isogenic 
models – reduced 
expression in shEPOR 
cells? 
       Lung tissue – 
 
 
 
 
 
 
 
 
FFPE, formalin-fixed paraffin wax-embedded; h-EPOR, human erythropoietin receptor; ECD, extracellular domain; N/E, not evaluated; N/A, not 
applicable. 
Shaded areas are meant to distinguish between peptide immunization and genetic immunization. 
 
and/or potential EPOR isoforms by Western blot; and those 
that would be useful for IHC studies of clinical   specimens. 
In  the  current  study,  peptide  immunization  was  used    
to generate antibodies for  assays  on  denatured  proteins,  
such as Western blotting and IHC, whereas novel genetic 
immunization protocols were used to generate antibodies that 
recognize EPOR in its native conformation for flow cytometry, 
immunofluorescence and IP assays. In total, 15 monoclonal 
antibody mother clones, were pretested in different assays for 
human EPOR. They comprised six rat monoclonal antibodies 
generated by immunization of synthetic peptides based on the 
cytoplasmic domain of the hEPOR, as well as four murine and 
five rat monoclonal antibodies generated against the hEPOR 
ECD domain by genetic immunization. 
The specificity of the EPOR antibodies has been validated 
by the use of EPOR-silenced cells. For example, we show that 
an endogenous Western blot signal using the GM1201 anti- 
body is specifically down-regulated in EPOR-silenced cells, 
strongly indicating that this antibody recognizes endogenous 
EPOR in these cells. Although the GM1201 antibody may  
also detect non-specific signals in the A549 cell line (Fig 3)  
the EPOR-silenced cells clearly permit  discrimination  
between a true EPOR-dependent signal and the non-specific 
signal. The number of monoclonal antibodies was reduced to   
a panel of four for Western blotting, IHC, IP, immunofluo- 
rescence and flow cytometry. 
For simplicity, the monoclonal antibodies have been sys- 
tematically named, based on an in-house nomenclature system 
at Aldevron Freiburg (see Table I). GM1201 is a rat monoclo- 
nal antibody raised against one of six synthetic peptides used to 
immunize rats, which is located in the cytoplasmic domain of 
hEPOR (Table I). This antibody reveals specific down-regu- 
lation of EPOR in EPOR-silenced MDA-MB-231 and A549 
cells, confirming that it also recognizes endogenous EPOR in 
these cells. Importantly, GM1201 was sensitive and specific in 
immunohistochemical studies of both cultured erythroid cells 
and bone marrow aspirates. For example using FFPE sections of 
bone marrow and bone marrow aspirates, it was possible to 
visualize erythroblastic islands in a patient with polycythaemia 
vera, and to demonstrate co-localization of EPOR with either 
ferritin H or glycophorin C in differentiating erythroid pro- 
genitors in a patient with erythroid hyperplasia. 
GM1202 and GM1203 are mouse monoclonal antibodies, 
raised by genetic immunization against the ECD of hEPOR.  
By co-localization of an ECFP-tagged EPOR and the signal 
obtained with our new antibodies GM1202 and GM1203 we 
show that GM1202 and GM1203 detect EPOR when it is 
expressed on the membrane (Fig 4). Furthermore,  GM1202 
and GM1203 have proved useful in immunopreciptation 
experiments in combination with GM1201 (Fig 7). GM1204   
is a rat monoclonal antibody raised by genetic immunization  
of the ECD of hEPOR which detects both human and mur-   
ine EPOR by FACS (mouse data not  shown). 
In a thorough, often overlooked study, Arcasoy et al (2003) 
isolated and characterized several novel cDNAs for EPOR 
splice variants expressed in cancer cells. Predicted amino acid 
sequences of these cDNAs indicated splice variants encoding 
soluble EPOR, variants containing insertions from intron 6 or 
intron 7, and membrane-bound EPOR peptides with intracy- 
toplasmic truncations. These multiple EPOR isoforms in 
human cancer cells may modulate the cellular effects of recom- 
binant EPO. Recently, Elliott et al (2013) reported on differ- 
ences in detection of EPOR in primary human tumour tissue 
samples using different antibodies. Using an anti-hEPOR 
monoclonal antibody, they could not detect EPOR protein in 
normal human and matching cancer tissues from breast, lung, 
colon, ovary or skin. Detection of EPOR in breast cancer tis- 
sues using a polyclonal antibody was interpreted as cross-reac- 
tivity. However, it cannot currently be ruled out that the 
epitope recognized by the specific monoclonal antibody could 
be missing in EPOR isoforms found in tumour tissues. 
The availability of monoclonal antibodies directed against 
specific exons, as those described herein, will enable, for the 
first time, the investigation of the resulting EPOR protein 
isoforms in different tissues. Thus, one antibody may recog- 
nize an epitope common to many EPOR isoforms,    indicating 
 Immunogen Antibody Isotype Epitope location UT-7 REH NALM-6 Difference? MDA-MB-231 A549 effective? 
1 Peptide GM1201 r-IgG2b h-EPOR 2+ 3+ 1+ Yes Yes Yes Yes 
 cytoplasmic 
domain 
2 Genetic GM1202 m-IgG1a h-EPOR ECD 3+ 3+ 2+ Yes No No No 
3 Immunization GM1203 m-IgG1a h-EPOR ECD 3+ 2+ 1+ Yes Yes No No 
4  GM1204 r-IgG2a h-EPOR ECD – N/E N/E N/A N/E N/E N/E 
 
 
a broader EPOR expression pattern compared to other anti- 
bodies whose epitope might only be present in fewer EPOR 
isoforms, with a more limited expression   pattern. 
The new antibodies will enable many interesting topics in 
EPOR biology to be explored.  These  include  resolution  of 
the major clinical question of which patients can be treated 
safely with EPO and its derivatives, dissection of the signal- 
ling mechanisms in non-erythroid cells and investigation of 
cancer cell:stromal cell interactions in  tumours. 
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